Fixed-Dose Combination of Memantine Extended Release and Donepezil for Alzheimer’s Disease: Licensing Application Submitted to FDA (Biospace Inc.)

Summary

A new drug application has been submitted to the FDA (in the United States) for a fixed-dose combination of memantine extended release and donepezil for the treatment of moderate to severe Alzheimer’s Disease dementia.

“Using the two drugs together appears to provide benefit over using acetylcholinesterase inhibitors alone. Reducing the number of pills by offering patients a fixed-dose combination helps lessen the daily medication burden and could improve patient adherence and compliance”.

Read more: Forest Laboratories and Adamas Pharmaceuticals Announce Forest’s Submission of New Drug Application for Memantine Extended Release and Donepezil Fixed-Dose Combination for Alzheimer’s Disease.

Reference

Forest Laboratories and Adamas Pharmaceuticals Announce Forest’s Submission of New Drug Application for Memantine Extended Release and Donepezil Fixed-Dose Combination for Alzheimer’s Disease. [Online, USA]: Biospace Inc., March 4th 2014.

About Dementia and Elderly Care News

Dementia and Elderly Care News. Wolverhampton Medical Institute: WMI. (jh)
This entry was posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Pharmacological Treatments, Quick Insights and tagged , , , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.